Kornimate/medical-research-clean huggingface dataset:
role of mdct in grading of esophageal varices

Conditions: MDCT Esoghageal Varices

Summary: esophageal varices are one of the major complications of liver cirrhosis.accurate grading of these varices is essential for effective management . traditionally, esophagogastroduodenoscopy is the gold standard for diagnosing and grading esophageal varices,multi detector computed tomography (mdct) has emerged as a non-invasive alternative for evaluating esophageal varices.it particularly appealing for patients who contraindicated to endoscopy .

esophageal varices are one of the major complications of liver cirrhosis, with an estimated prevalence of approximately 80% with decompensated patients and 50% in compensated cirrhosis, pose a significant risk of life-threatening of bleeding due to portal hypertension. accurate grading of these varices is essential for effective management . traditionally, esophagogastroduodenoscopy (egd) is the gold standard for diagnosing and grading esophageal varices . it provides direct visualization, allowing for detailed assessment of variceal size and other risk factors for bleeding . however, it is an invasive procedure that requires sedation and carries some risks, such as bleeding or perforation . multi detector computed tomography (mdct) has emerged as a non-invasive alternative for evaluating esophageal varices. it offers detailed cross-sectional images and is widely available, providing a broader assessment of abdominal pathology. its non-invasive nature makes it particularly appealing for patients who contraindicated to endoscopy .

Eligibility criteria:
inclusion criteria: -cirrhotic patients with portal hypertension undergoing upper gi endoscopy. exclusion criteria: -contraindication to contrast:( severe renal insufficiency, allergy to contrast agents). -previous history of upper gi endoscopy with intervention (band ligation or sclerotherapy).- * pregnancy. * patients with previous transjagular intrahepatic portosystemic shunt (tips). * patients with contraindication to endoscopy (severe cardiopulmonary conditions, coma "unless the patient is intubated", and cardiac arrhythmias)

Keywords: mdct esophageal varices
on-lay versus pre-peritoneal hernioplasty in incisional lumbar hernia

Conditions: Lumbar Hernia

Summary: to compare between the outcome of on-lay and pre-peritoneal techniques of hernioplasty in incisional lumbar hernia repair.

lumbar hernia is found as a challenge even in the era of advanced medicine, due to its rarity which complicate its diagnosis and treatment\[1\]. lumbar hernia is the protrusion of an organ intra-peritoneal or extra-peritoneal tissue through a congenital or acquired defect in the posterolateral abdominal wall\[2\]. incisional lumbar hernia is among the types of lumbar hernia that accounts for 25% of cases\[3\]. post abdominal surgeries, the tissue strength can only regain 80% of its maximum tensile power under perfect conditions. thus, each abdominal surgery is a predisposing factor for lumbar incisional hernia \[4\] primary closure of the defect with sutures, has proven to have a high failure rate so the integration of the mesh in hernia repair has significantly flattened the recurrence curve. taking the advantage of laplace's law, the mesh aims to reinforce or bridge the defect and distribute the intra-abdominal pressure across the entire synthetic sheet rather than just the defect. \[5\] the two most used mesh placing techniques are on-lay and pre-peritoneal. each method has its benefits and drawbacks. \[6\] some surgeons outweigh the on-lay technique to avoid extensive dissection. thus, it is a faster and easier technique; nevertheless, there are several local wound issues. \[7\] the pre-peritoneal method allows the surgeon to apply the mesh posterior to the fascial plane in front of the peritoneum. the latter technique is gaining popularity with time \[8\] literature are deficient in comparing on-lay and pre-peritoneal technique in the repair of incisional lumbar hernia.

Eligibility criteria:
inclusion criteria: * incisional lumbar hernia * recurrent lumbar hernia * age more than 16 years old exclusion criteria: * complicated lumbar hernia (irreducible, obstructed, strangulated hernia) * denovo lumbar hernia
a phase iii clinical trail to evaluate the efficacy, safety, pharmacokinetics and immunogenicity characteristics of gr2001 injection

Conditions: Tetanus

Summary: the goal of this clinical trial is to compare the efficacy and safety of gr2001 injection with human tetanus immunoglobulin(htig) in tetanus prophylaxis. patients will receive either gr2001 injection or htig on study d0.


Eligibility criteria:
inclusion criteria: 1. chinese male or female adults aged ≥ 18 years； 2. participants with suspected tetanus exposure (due to dirty or contaminated wounds from various injuries); 3. participants who provide signed written informed consent form. exclusion criteria: 1. participants known to be allergic to the investigational medicinal product or those suffering from severe allergic conditions； 2. suspect or diagnosed as tetanus; 3. previously diagnosed as immunoglobulin a (iga) deficiency with anti-iga antibodies； 4. prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine; 5. females who are pregnant or with pregnancy test positive.

Keywords: tetanus human tetanus immunoglobulin gr2001 injection
perioperative dexamethasone reduces postoperative pain and nausea after hip arthroscopy

Conditions: Pain, Postoperative; Nausea, Postoperative; Opioid Use

Summary: the purpose of this study is to assess the effect of dexamethasone on postoperative pain and nausea after hip arthroscopy.

hip arthroscopy (has) is a standard procedure with good mid and long-term results. postoperative pain is a great concern and postoperative pain management of great importance. high demand for opiates and the associated side effects especially nausea limit the postoperative rehabilitation. promising results to reduce postoperative pain and nausea have been achieved by perioperative dexamethasone, which has a strong anti-inflammatory effect reducing pain and inflammation as well as a strong anti-emetic effect, especially in total hip replacement. it is our goal to compare the effect of perioperative intravenous dexamethasone (3x 4mg amp. fortecortin =12mg prior to surgery and 3x4mg amp. fortecortin = 12mg at 8.00am of the first postoperative day in 250ml saline solution) to a control group (placebo) (1x 250ml saline solution postoperative day 1 at 8.00am) regarding pain level, opiate consumption, postoperative nausea and patient satisfaction. a double-blinded prospective randomized control trial including 60 patients receiving elective unilateral has will be conducted.

Eligibility criteria:
inclusion criteria: * • age ≥ 18 years * general anasthesia * elective isolated unilateral has for any reason * no prior hip surgery * written informed consent as documented by signature (appendix informed consent form) * competent german language skills exclusion criteria: * • chronic pain patient, chronic lower back pain * steroid or immunosuppressive drugs used within 6 months of surgery * renal failure, hepatic failure * relevant allergies * pregnancy/ breast feeding * contraindications for fortecortin treatment according to swissmedic * previous enrollment into the current study * participation in another study with investigational drug within the 30 days preceding and during the present study * known or suspected non-compliance, drug or alcohol abuse * illness according to "warnings and precautions of dexamethasone and nacl"
effectiveness of bobath/halliwick on children with cerebral palsy

Conditions: Cerebral Palsy

Summary: investigation of the effectiveness of water based therapy on children with cerebral palsy (cp)

the purpose of this randomized controlled trial was: to examine the effectiveness of the halliwick concept intervention in water approach for people with motor deficiency and, more specifically, for children with diagnosed cerebral palsy. in a second phase, to compare the contribution of water intervention to the child's motor development against just bobath physiotherapeutic intervention, in terms of the milestones of gross motor skills of the children over time. the aim of the research is to determine the contribution of the halliwick concept- hydrotherapeutic intervention approach in the psychomotor development in children with cerebral palsy and to explore its contribution to a comprehensive therapeutic approach for these children. it is a fact that, in recent years, parallel therapeutic approaches have gained ground, which, in combination with the physiotherapeutic treatment, contributes to the enhancement of therapeutic effects in early and follow-up intervention for children with cerebral palsy. the study resulted from the fact that there is not such a large-scale study in greece. also, there are few published studies in the world, trying to evaluate the therapeutic benefit of the halliwick concept as an hydro-therapeutic approach.

Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy * not have some type of surgery or botulinum toxin infusion in the last year. * the children with cognitive limitations were selected, in order to be able to execute elementary commands. * attending treatment program by the same therapist, either on water, or on land. exclusion criteria: * children with autism * children who had some scheduled surgery or botulinum toxin injection. * children with severe vision problems * children who could not follow the verbal instructions or reproduce a test reproduction. * children who were absent from the treatment program either in the water or on land for over a week

Keywords: aquatic therapy pediatrics cerebral palsy bobath halliwick
in vitro follicle activation

Conditions: Primary Ovarian Insufficiency; Infertility

Summary: the purpose of this study is to evaluate the effectiveness of an experimental treatment, known as in vitro activation (iva) of dormant ovarian follicles, for infertility in women diagnosed with primary ovarian insufficiency (poi).

the purpose of this study is to evaluate the effectiveness of an experimental treatment, known as in vitro activation (iva) of dormant ovarian follicles, for infertility in women diagnosed with primary ovarian insufficiency (poi; also known as premature ovarian failure). patients diagnosed with poi are infertile due to a lack of follicle growth and ovulation; oocyte donation is the only treatment option currently available to enable these women to have a child. iva treatment may result in the rescue of the remaining primordial follicles within the ovary, thus making oocytes available for ivf, embryo production, transfer and pregnancy. in this experimental treatment, ovarian tissue is removed from the patient and cultured in vitro for 48 hours with specific compounds to activate dormant primordial follicles. following activation ovarian tissue is auto-grafted to the serosa of the fallopian tube, and the patient is monitored for signs of follicle growth. growing follicles are stimulated with exogenous hormones, followed by oocyte retrieval and ivf.

Eligibility criteria:
inclusion criteria: * women diagnosed with primary ovarian insufficiency (poi), seeking pregnancy and eligible for ivf at colorado center for reproductive medicine (lone tree, co). * patients can be of any race, culture, sexual orientation or ethnicity. exclusion criteria: * minors are excluded from participation in this study.

Keywords: reproductive techniques, assisted ovarian follicle
free-living physical activity and energy expenditure

Conditions: Obesity

Summary: we have recently validated a new device for measurement of physical activity and found it to detect type, duration and intensity of many types of physical activity at better than 98% accuracy. after further validating this device to determine if it can also accurately assess energy expenditure, we will use it to collect cross-sectional data on free-living physical activity and energy expenditure in adolescent girls.


Eligibility criteria:
study3: healthy lean and obese adults, at least 18 years of age.
2 years prospective study to collect real-life data on the retention, quality of life, effectiveness and treatment pattern of secukinumab in adult patients with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis

Conditions: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis; Non-radiographic Axial Spondyloarthritis

Summary: this is an observational, prospective primary data collection study. the duration of observation is 2 years after study enrolment date. disease and treatment history will be retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthropathy).

after the baseline visit, data will be collected for each patient prospectively every 6 months for up to 2 years. at each visit, effectiveness parameters, as well as the patients' qol and treatment pattern will be documented.

Eligibility criteria:
inclusion criteria: 1. written informed consent of the patient to participate in the study 2. age 18-80 years. 3. patients with an assured diagnosis by the treating physician of active moderate to severe plaque psoriasis or active psa or active as or active non-radiographic axial spa. 4. patients must have received the official approval to receive secukinumab in dermatology disease prior authorization (ddpa) or rheumatology disease prior authorization (rdpa) before study participation or the decision to treat patient's condition with secukinumab is happened before entering the study 5. patients must receive the first dose of secukinumab during the study enrollment period. 6. patients for whom the decision for a therapy with secukinumab is made by the attending treating physician, regardless of this non-interventional study. 7. patients who have eq-5d score before start the 1st dose secukinumab. exclusion criteria: 1. any medical or psychological condition in the treating physician's opinion which may prevent the patient from study participation for the 2 year study period.\* 2. patients participating in parallel in other interventional clinical trial. 3. patients participated in an interventional clinical trial with secukinumab involvement in the past. * note: for example, patients diagnosed with a terminal illness and those with cognitive impairment due to dementia and alzheimer's disease.

Keywords: moderate to severe plaque psoriasis psoriatic arthritis ankylosing spondylitis non-radiographic axial spondyloarthritis nis thailand secukinumab
role of hiv on glutathione synthesis and oxidative stress

Conditions: HIV Infection; Erythrocyte Glutathione Deficiency

Summary: hiv infection is associated the development of increased oxidative stress and deficiency of glutathione (gsh), the dominant endogenous antioxidant protein, but the underlying mechanisms contributing to gsh deficiency are hitherto unknown. furthermore gsh metabolism has not been studied in hiv patients, in whom the burden of risk factors promoting oxidative stress is highest. our previous studies in non-hiv human subjects with diabetes-related oxidative stress and gsh deficiency have demonstrated that the latter is due to decreased synthesis of gsh. importantly, short-term dietary supplementation with the simple gsh precursor amino-acids cysteine and glycine, boosted gsh synthesis and cellular concentrations, corrected gsh deficiency, and reduced oxidative stress and oxidant damage. the current proposal will study whether (1) defective synthesis underlies gsh deficiency in patients with hiv, and will test a simple, inexpensive and rational therapy based on protein supplementation to improve gsh synthesis and concentrations and lower markers of oxidative stress and oxidant damage in these patients; (2) study if correction of gsh deficiency is asssociated with any changes in (a) impaired mitochondrial fuel oxidation in the fasted and insulin stimulated states; (b) insulin sensitivity; (c) body composition and anthropometry; (d) forearm muscle strength; (e) plasma biochemistry, and (f) quality of life indices in these subjects.


Eligibility criteria:
inclusion criteria: (1) hiv infected patients with gsh deficiency exclusion criteria: 1. renal impairment (serum creatinine above 1.5mg/dl), liver impairment (alt and ast \> 2x upper limit of normal) 2. any hormonal disorders such as hypothyroidism, hypercortisolemia, hypogonadism, or diabetes mellitus on pharmacotherapy 3. evidence of infections other than hiv in the preceding 3 months 4. subjects with plasma triglyceride concentrations of ≥ 500mg/dl on triglyceride lowering therapy 5. bmi \< 20 6. established heart disease 7. co-existing viral hepatitis b and c
hepatic transarterial administrations of nkr-2 in patients with unresectable liver metastases from colorectal cancer

Conditions: Colon Cancer Liver Metastasis

Summary: the purpose of this study is to test an experimental anti-cancer immunotherapy called nkr-2 (modified t cells), to treat colorectal cancer with unresectable liver metastases. the trial will test three dose levels (dose escalation). at each dose, the patients will receive three successive hepatic transarterial administrations, two weeks apart, of nkr-2 cells. the study will enroll up to 18 patients.


Eligibility criteria:
inclusion criteria: * the patient must be ≥ 18 years old at the time of signing the icf. * the patient must have a histologically proven adenocarcinoma of the colon or rectum. * the patient must have liver metastases non treatable with curative intent by surgical resection or local ablation at the time of registration. * the patient must have measurable hepatic metastases defined by recist version 1.1 for solid tumors. * the patient must have received one prior chemotherapy line for metastatic disease and have developed resistance or intolerance to this treatment. * the patient must have an ecog performance status 0 or 1. * the patient must have the bone marrow reserve, hepatic and renal functions exclusion criteria: * patients who are presenting evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis as determined by clinical or radiologic assessment. * patients who are planned to receive or concurrently receiving any non-cancer-directed investigational agent, or have received a non-cancer directed investigational agent within 3 weeks before the planned day for the first nkr-2 administration. * patients who are scheduled to receive concurrent growth factor (except erythropoietin), systemic steroid, other immunosuppressive therapy or cytotoxic agents (systemic or localized) other than the treatment authorized per protocol. * patients who underwent major surgery within 4 weeks before the planned day for the first nkr-2 administration. * patients who have received a live vaccine ≤ 6 weeks prior to the planned day for the first nkr-2 administration. * patients with a family history of congenital or hereditary immunodeficiency. * patients with history of any autoimmune disease.
a clinical study to investigate the reliability of fetal heart rate and maternal heart rate signals extracted from biopotential data

Conditions: Pregnancy Related

Summary: bloom technologies is developing a wearable device for monitoring pregnancy. in this study, bloom technologies wants to investigate the reliability of this new technology. for this reason, a device that records very high-quality data (g,hlamp) was chosen. the study device is attached to the body by means of electrodes (up to 32) that can be safely attached to the skin. most of the electrodes are placed on the abdomen, and a few on the chest and back.


Eligibility criteria:
inclusion criteria: * pregnant woman ≥ 18 years old * gestational age ≥ 30 weeks and 0 days * singleton pregnancy * ability to read and understand english or spanish * willingness to participate in the study exclusion criteria: * implanted pacemaker or any other implanted electrical device * history of allergies to skin adhesives * irritated or lesioned skin at the electrodes locations
a study on oral vitamin d megadoses

Conditions: Hypovitaminosis D

Summary: the purpose of this study is to determine if infrequent administration of oral vitamin d megadoses is effective treatment to maintain serum 25-hydroxyvitamin d(3) above target levels of 50-75 nmol/l. the investigators hypothesize that 100 000 iu or at least 200 000 iu vitamin d3 in every three months would be effective and safe treatment to achieve the target levels.


Eligibility criteria:
inclusion criteria: * female * 70-80 yrs old exclusion criteria: * disease or medication affecting calcium homeostasis * renal failure (pt-gfre-cg \< 35 ml/min)

Keywords: vitamin d supplementation cholecalciferol pth bone turnover markers elderly women
adjuvant chemoradiotherapy prior to surgery in stage iva oral cancers

Conditions: Squamous Cell Carcinoma of Oral Cavity

Summary: oral cancer is the single largest cancer in males in india. 90-95% cases of oral cancer are squamous cell carcinomas and many of them present at late stages (t3 and above). treatment of oscc includes single modality surgery, radiotherapy, or combinations of these modalities with or without systemic therapy. for unresectable cases, radiotherapy and/or chemotherapy is the treatment modality. efficacy of neoadjuvant chemoradiotherapy for resectable stage iv tumors (late stage) needs to be evaluated to assess its benefit before surgery.

this study will assess the benefit of preoperative adjuvant chemoradiotherapy in patients with an stage iva oral squamous cell carcinoma (oscc). the study population will consist of patients who have not been treated previously. patients satisfying the inclusion-exclusion criteria will be included in the study after obtaining a valid, written and informed consent. after reviewing the histopathological report, the patients will be treated as per the study protocol. the patients will be under regular follow-up with 3 monthly intervals for a period of one year and 6 monthly period in the following years. at each follow-up, patients will be evaluated clinically for evidence of locoregional tumor recurrence. the locoregional recurrence-free survival will be calculated based on the difference between the date of inclusion and the date of biopsy-proven recurrence. we will also record the overall survival, parameters like trismus, osteonecrosis and xerostomia. quality of life will be assessed at a regular interval of 1 year using the university of washington quality of life questionnaire (uw-qol v.4) study protocol: 1. preoperative radiotherapy over 5 weeks- dose 180-200cgys per day/ total 4500 cgys 2. three weekly concurrent chemotherapy with cisplatin 100 mg /m2 3. initial surgery in leg for prefabrication of fibula - 2 weeks after starting of radiotherapy treatment. delay is required for planning of implant position in the fibula. 4. definitive surgical procedure with reconstruction by prefabricated flap, 6 weeks post radiotherapy.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed stage iva squamous cell carcinoma of the oral cavity. 2. surgically resectable oral squamous carcinoma with invasion of mandible or maxilla. 3. newly diagnosed or previously untreated squamous cell carcinoma of the oral cavity. exclusion criteria: 1. patients with distant metastases. 2. patients with contraindication to radiotherapy. 3. patients with vascular disorders or ischemic heart disease. -

Keywords: oral neoplasms mouth neoplasms